Biochemical parameters in cystic fibrosis patients
| Subjects n | Concentration | RR | >RR % | <RR % | |
| Bone metabolism markers | |||||
| 25-hydroxyvitamin D nM | 84 | 60.0 (35.0–83.5) | 38–108 | 10.7 | 27.4 |
| Osteocalcin µg·L−1 | |||||
| Males | 46 | 16 (12–25) | 12.1–18.9 | 47.8 | 28.3 |
| Females | 34 | 10.5 (7.3–16.0) | 6.2–19.0 | 14.7 | 14.7 |
| Urinary NTx nmol BCE·mmol UCr−1 | |||||
| Males | 47 | 48.3 (40.6–85.4) | 19.6–62.6 | 36.2 | 4.3 |
| Females | 34 | 39.1 (28.4–64.6) | 11.5–62.3 | 29.4 | 0 |
| Alkaline phosphatase U·L−1 | 85 | 112 (93–137) | <110 | 52.9 | 0 |
| Calcium mM | 85 | 2.33±0.12 | 2.1–2.6 | 0 | 2.4 |
| Phosphate mM | 85 | 1.24±0.24 | 0.7–1.3 | 34.1 | 3.5 |
| Parathyroid hormone pM | 85 | 4.5±3.6 | 1.3–7.6 | 14.6 | 11.0 |
| Hormones | |||||
| Testosterone (males) nM | 49 | 14.8 (12.5–20.0) | 6.9–28.1 | 6.1 | 0 |
| Oestradiol (females) pM | 32 | 212 (154–392) | 143–1864 | 0 | 21.9 |
| LH U·L−1 | |||||
| Males | 48 | 5.15 (3.65–7.00) | 2–12 | 6.3 | 4.2 |
| Females | 32 | 6.90 (3.55–9.55) | 0.4–105 | 0 | 0 |
| FSH U·L−1 | |||||
| Males | 48 | 5.25 (4.65–7.05) | 1–8 | 18.9 | 0 |
| Females | 32 | 5.55 (4.10–7.10) | 2–22 | 0 | 9.4 |
| SHBG nM | |||||
| Males | 49 | 29 (24–33) | 13–70 | 0 | 8.2 |
| Females | 33 | 53 (29–124) | 11–114 | 15.2 | 0 |
| TSH mU·L−1 | 84 | 1.62±0.92 | 0.4–4.7 | 1.2 | 1.2 |
| Inflammatory markers | |||||
| Albumin g·L−1 | 85 | 35.3±3.2 | 35–52 | 0 | 38.9 |
| TNF-α pg·mL−1 | 80 | 5.45 (ND–7.30) | <11.7 | 6.3 | 0 |
| IL-6 pg·mL−1 | 81 | 6.3 (ND–10.1) | <10.4 | 23.4 | 0 |
Data are presented as mean±sd or median (interquartile range). Reference ranges (RRs) are those reported by the testing laboratory, except for interleukin (IL)-6 and tumour necrosis factor-α (TNF-α), for which the reference ranges are the lower 95% range of the healthy volunteers tested. NTx: N-telopeptide; LH: luteinising hormone; FSH: follicle-stimulating hormone; SHBG: sex-hormone-binding globulin; TSH: thyroid-stimulating hormone; ND: not detected.